Pharmaceutisch Weekblad

, Volume 7, Issue 5, pp 208–211 | Cite as

Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist

  • A. S. Horn
  • P. Tepper
  • J. Van Der Weide
  • M. Watanabe
  • D. Grigoriadis
  • P. Seeman
Short Communications


The synthesis of a new, potent and selective D2 dopamine receptor agonist, N-0437, of the 2-aminotetralin group is described. The results of a radioreceptor binding assay using a homogenate of porcine anterior pituitary as a tissue source for D2 dopamine receptors and3H-spiperone as radioligand demonstrate that this compound is one of the most potent compounds so far evaluated in this test system.


Public Health Internal Medicine Dopamine Dopamine Receptor Binding Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Schachter M, Bedard P, DeBono AG, et al. The role of D-1 and D-2 receptors. Nature 1980;286:157–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Seeman P. Brain Dopamine Receptors. Pharmacol Rev 1980;32:229–313.PubMedGoogle Scholar
  4. 4.
    Nedelec L, Dumont C, Oberlander C, Frechet D, Laurent J, Boissier JR. Synthèse et étude de l'activité dopaminergique de dérivés de la di(phénéthyl)amine. Eur J Med Chem 1978;13:553–63.Google Scholar
  5. 5.
    Sumners C, Dijkstra D, De Vries JB, Horn AS. Neurochemical and behavioural profiles of five dopamine analogues. Naunyn Schmiedebergs Arch Pharmacol 1981:316:304–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Horn AS, Tepper P, Kebabian JW, Beart PM. N-0434, a very potent and specific new D-2 dopamine receptor agonist. Eur J Pharmacol 1984:99:125–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Beaulieu M, Itoh Y, Tepper P, Horn AS, Kebabian JW.N, N-Disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists. Eur J Pharmacol 1984:105:15–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Horn AS. U.S. patent no. 4,465,692. 1984.Google Scholar
  9. 9.
    Feenstra MGP, Sumners C, Goedemoed JH, De Vries JB, Rollema H, Horn AS. A comparison of the potencies of various dopamine receptor agonists in models of pre- and postsynaptjc receptor activity. Naunyn Schmiedebergs Arch Pharmacol 1983:324:108–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Hacksell U, Svensson U, Nilsson JLG, et al.N-Alkylated 2-aminotetralins: Central dopamine receptor stimulating activity. J Med Chem 1979;22:1469–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Janssen PAJ, Van der Eycken CAM. The chemical anatomy of potent morphine-like analgesics. In: Burger A, ed. Drugs Affecting the Central Nervous System. New York: Marcel Dekker, 1968:37.Google Scholar
  12. 12.
    Van Oene JC, De Vries JB, Dijkstra D, Renkema RJW, Tepper PG, Horn AS.In vivo dopamine autoreceptor selectivity appears to be critically dependent upon the aromatic hydroxyl position in a series ofN,N-disubstituted 2-aminotetralins. Eur J Pharmacol 1984;102:101–15.PubMedGoogle Scholar
  13. 13.
    Ames DE, Evans D, Grey TF. Islip PJ, Richards KE. Synthesis of alkoxy-1,2,34-tetrahydronaphthalene derivatives. J Chem Soc 1965:2636–41.Google Scholar
  14. 14.
    Trapani G, Reho A, Latrofa A. Trimethylamine-Borane as useful reagent in theN-acylation orN-alkylation of amines by carboxylic acids. Synthesis 1983:1013–4.Google Scholar
  15. 15.
    Grigoriadis D, Seeman P. The dopamine/neuroleptic receptor. Can J Neurol Sci 1984:11:108–13.PubMedGoogle Scholar
  16. 16.
    Munson P, Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980:107:220–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Seeman P, Grigoriadis D, George SR, Watanabe M, Ulpian C. Functional States of Dopamine Receptors in Dopaminergic Systems and Their Regulation. In: Woodruff GN, Creese I, Gessa GL, Hornykiewicz O, Poat JA, Roberts PJ, eds. London: MacMillan Press (in press).Google Scholar
  18. 18.
    Seiler MP, Markstein R. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Mol Pharmacol 1984:26:452–7.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1985

Authors and Affiliations

  • A. S. Horn
    • 1
  • P. Tepper
    • 1
  • J. Van Der Weide
    • 1
  • M. Watanabe
    • 2
  • D. Grigoriadis
    • 2
  • P. Seeman
    • 2
  1. 1.Department of PharmacyUniversity of GroningenAW GroningenThe Netherlands
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada

Personalised recommendations